Objective:To observe the clinical efficacy of “Shenqi No.1 Prescription” combined with routine treatment of western medicine in the treatment of early diabetic kidney disease(DKD). Methods89 patients with early DKD patients were randomly divided into the treatment group(45 cases) and control group(44 cases). The control group was treated with the routine treatment of western medicine,the treatment group was treated with “Shenqi No.1 Prescription” based on the treatment for the control group,with a course of 6 months. The changes on the indexes such as fasting plasma glucose(FPG),2 h postprandial glucose(2hPG),glycosylated hemoglobin(HbA1c),homeostasis model assessment of insulin resistance(Homa-IR),urinary microalbumin(mALB),serum creatinine(Scr) and glomerular filtration rate(eGFR) were observed.  Results:①Compared with treatment before,there were statistically significant differences on the levels of 2hPG,HbA1c and Homa-IR in the treatment group after treatment(P<0.05),but no statistically significant differences on all the glycemic indexes in the control group were observed after treatment(P>0.05). After treatment, there was statistically significant difference on Homa-IR level between the two groups(P<0.05). ②Compared with treatment before,there was statistically significant difference on the mALB level in the treatment group after treatment(P<0.05). After treatment,the mALB level in the treatment group was obviously lower than that in the control group(P<0.05).  Conclusion:“Shenqi No.1 Prescription” combined with routine treatment of western medicine in the treatment of early diabetic kidney disease can improve the insulin resistance, stabilize the blood glucose,protect the renal function, and thus delay the disease progression and ameliorate the prognosis of patients.